ES2188929T3 - Analogos 2-peptidicos de tipo glucagon. - Google Patents

Analogos 2-peptidicos de tipo glucagon.

Info

Publication number
ES2188929T3
ES2188929T3 ES97916280T ES97916280T ES2188929T3 ES 2188929 T3 ES2188929 T3 ES 2188929T3 ES 97916280 T ES97916280 T ES 97916280T ES 97916280 T ES97916280 T ES 97916280T ES 2188929 T3 ES2188929 T3 ES 2188929T3
Authority
ES
Spain
Prior art keywords
glucagon
analogs
glucagon type
peptidal
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916280T
Other languages
English (en)
Inventor
Daniel J Drucker
Anna E Crivici
Martin Sumner-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1149336 Ontario Inc
NPS Allelix Corp Canada
Original Assignee
1149336 Ontario Inc
NPS Allelix Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2188929(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 1149336 Ontario Inc, NPS Allelix Corp Canada filed Critical 1149336 Ontario Inc
Application granted granted Critical
Publication of ES2188929T3 publication Critical patent/ES2188929T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

ANALOGOS DEL PEPTIDO - 2 TIPO GLUCAGON, UN PRODUCTO DE EXPRESION GENICA DE GLUCAGON, SE HAN IDENTIFICADO COMO FACTORES DE CRECIMIENTO DEL TEJIDO INTESTINAL. SE DESCRIBE SU FORMULACION PARA SU USO FARMACEUTICO Y TERAPEUTICO EN EL TRATAMIENTO DE TRASTORNOS DEL INTESTINO DELGADO.
ES97916280T 1996-04-12 1997-04-11 Analogos 2-peptidicos de tipo glucagon. Expired - Lifetime ES2188929T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63127396A 1996-04-12 1996-04-12

Publications (1)

Publication Number Publication Date
ES2188929T3 true ES2188929T3 (es) 2003-07-01

Family

ID=24530501

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97916280T Expired - Lifetime ES2188929T3 (es) 1996-04-12 1997-04-11 Analogos 2-peptidicos de tipo glucagon.
ES01129072T Expired - Lifetime ES2351661T3 (es) 1996-04-12 1997-04-11 Péptido-2 análogo al glucagón.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01129072T Expired - Lifetime ES2351661T3 (es) 1996-04-12 1997-04-11 Péptido-2 análogo al glucagón.

Country Status (16)

Country Link
EP (5) EP0906338B1 (es)
JP (3) JP4148994B2 (es)
CN (1) CN1268640C (es)
AT (2) ATE227309T1 (es)
AU (1) AU733857B2 (es)
BR (1) BRPI9708566B8 (es)
CA (1) CA2251576C (es)
DE (2) DE60142885D1 (es)
DK (2) DK1231219T3 (es)
ES (2) ES2188929T3 (es)
FR (1) FR13C0013I2 (es)
HK (1) HK1050204B (es)
LU (1) LU92153I2 (es)
NZ (1) NZ332281A (es)
PT (2) PT906338E (es)
WO (1) WO1997039031A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE60142885D1 (de) 1996-04-12 2010-10-07 Ontario Inc 1149336 Dem Glukagon ähnliches Peptid-2
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
DK0981362T3 (da) * 1997-05-16 2004-03-15 Ontario Inc 1149336 Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
AU2712899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
WO1999058144A1 (en) * 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
ES2310192T3 (es) 2000-09-18 2009-01-01 Sanos Bioscience A/S Uso de peptidos glp-2.
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
DE602004031927D1 (de) 2003-02-04 2011-05-05 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
ES2330335T3 (es) * 2003-08-21 2009-12-09 Novo Nordisk A/S Purificacion de peptidos tipo glucagon.
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
ES2427150T3 (es) 2004-11-01 2013-10-29 Nps Pharmaceuticals, Inc. Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
AU2007319066B2 (en) * 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
AU2010312655A1 (en) * 2009-10-30 2012-05-03 Glytech, Inc. Glycosylated form of antigenic GLP-1 analogue
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US20130157954A1 (en) * 2010-05-11 2013-06-20 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
US20140249090A1 (en) 2011-04-01 2014-09-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
AU2013255752B2 (en) 2012-05-03 2017-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
CN103159848B (zh) * 2013-01-06 2015-11-25 中国人民解放军第四军医大学 人胰高血糖素样肽-2二串体蛋白及其制备方法
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
WO2018069442A1 (en) * 2016-10-12 2018-04-19 University Of Copenhagen Peptide dual agonists of gipr and glp2r
AU2017371516C1 (en) 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
BR112019026711A2 (pt) 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3924369A1 (en) 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
BR112021020941A2 (pt) 2019-06-14 2021-12-21 Zealand Pharma As Composição farmacêutica parenteral isotônica, método para melhoria da estabilidade química da dita composição e uso de manitol
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
JP2024547006A (ja) * 2021-12-17 2024-12-26 バイナン バイオテック エーピーエス Ｇｉｐｒ及びｇｌｐ－２ｒのペプチド二重アゴニスト

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DE69717092T2 (de) 1996-03-01 2003-07-24 Novo Nordisk A/S, Bagsvaerd Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid
DE60142885D1 (de) * 1996-04-12 2010-10-07 Ontario Inc 1149336 Dem Glukagon ähnliches Peptid-2
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Also Published As

Publication number Publication date
EP1231219A1 (en) 2002-08-14
EP2218734A2 (en) 2010-08-18
JP2008184465A (ja) 2008-08-14
DK1231219T3 (da) 2010-12-20
CA2251576A1 (en) 1997-10-23
EP2218734B1 (en) 2013-06-05
EP1231219B1 (en) 2010-08-25
JP2007204491A (ja) 2007-08-16
DE69716905D1 (de) 2002-12-12
WO1997039031A1 (en) 1997-10-23
ES2351661T3 (es) 2011-02-09
PT1231219E (pt) 2010-11-30
PT906338E (pt) 2003-03-31
CA2251576C (en) 2012-08-21
LU92153I2 (fr) 2013-04-19
JP5019466B2 (ja) 2012-09-05
EP2009024A1 (en) 2008-12-31
DE60142885D1 (de) 2010-10-07
JP2000511881A (ja) 2000-09-12
ATE227309T1 (de) 2002-11-15
EP0906338B1 (en) 2002-11-06
HK1050204B (en) 2011-09-23
DK0906338T3 (da) 2003-03-03
JP4148994B2 (ja) 2008-09-10
BRPI9708566A (pt) 2000-01-04
FR13C0013I2 (fr) 2013-08-16
HK1147761A1 (en) 2011-08-19
ATE478892T1 (de) 2010-09-15
NZ332281A (en) 2000-03-27
EP0906338A1 (en) 1999-04-07
DE69716905T2 (de) 2003-07-24
HK1050204A1 (en) 2003-06-13
CN1268640C (zh) 2006-08-09
AU733857B2 (en) 2001-05-31
HK1033324A1 (en) 2001-08-24
EP2275438A1 (en) 2011-01-19
BR9708566B1 (pt) 2012-09-04
CN1244872A (zh) 2000-02-16
BRPI9708566B8 (pt) 2022-01-18
AU2500297A (en) 1997-11-07
JP4149497B2 (ja) 2008-09-10
FR13C0013I1 (es) 2013-05-04
EP2218734A3 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
ES2188929T3 (es) Analogos 2-peptidicos de tipo glucagon.
CY2615B2 (en) Glucagon-like peptide-2 and its therapeutic use
AR013612A1 (es) Colostrinina y usos de la misma para la manufactura de un medicamento, una composicion farmaceutica que la comprende, uso de la misma como suplemento dedieta, un suplemento de dieta, un nonapeptido, el uso del mismo para la manufactura de un medicamento, composicion farmaceutica y metodo para prepar
ES2191192T3 (es) Tienopirimidinas.
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
PT703786E (pt) Utilizacao de nonapeptideos e decapeptideos para a preparacao de um medicamento para o tratamento da sida
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
ES2185897T3 (es) Uso de 2-carnitinas de alcanoilo para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias del intestino.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
DE3770766D1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
ES2175582T3 (es) Cromanos sustituidos con sulfonamida, procedimiento para su preparacion, su utilizacion como medicamento, asi como preparados farmaceuticos que los contienen.
ES2188140T3 (es) Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento.
MX2023013301A (es) Una pluralidad de particulas tasquinimod y su uso.
AR008083A1 (es) Composiciones farmaceuticas y el uso de compuestos para preparar medicamentos para tratar desordenes del snc.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
ES1034986Y (es) Aparato para el tratamiento del cuerpo humano.
ATE494239T1 (de) Vorrichtung zum abgeben von pharmazeutischen produkten
MY112888A (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative